✦ LIBER ✦

An Antibody-Drug Conjugate Is Effective in HER2-Positive Breast Cancer

Book ID: 118019024
Publisher: American Association for Cancer Research
Year: 2012
Tongue: English
Weight: 297 KB
Volume: 2
Category: Article
ISSN: 2159-8274
DOI: 10.1158/2159-8290.cd-rw2012-173

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trastuzumab cost effective in HER2-posit

Trastuzumab cost effective in HER2-positive breast cancer

📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl ⚖ 125 KB

Trastuzumab cost effective in HER2-posit

Trastuzumab cost effective in HER2-positive breast cancer

📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl ⚖ 126 KB

Phase I Study of Trastuzumab-DM1, an HER

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

✍ Krop, I. E.; Beeram, M.; Modi, S.; Jones, S. F.; Holden, S. N.; Yu, W.; Girish, 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 153 KB

Targeting HER2-positive cancer with dola

Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates

✍ Gianolio, Diego A.; Rouleau, Cecile; Bauta, William E.; Lovett, Dennis; Cantrell 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 615 KB

Ado-trastuzumab emtansine (T-DM1): a nov

Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer

✍ Baron, J. M.; Boster, B. L.; Barnett, C. M. 📂 Article 📅 2014 🏛 SAGE Publications 🌐 English ⚖ 165 KB

Clinical pharmacology of trastuzumab emt

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

✍ Sandhya Girish; Manish Gupta; Bei Wang; Dan Lu; Ian E. Krop; Charles L. Vogel; H 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 520 KB